[go: up one dir, main page]

MX2007003994A - Composici??n farmaceutica para el tratamiento de xeroftalmia y xerostomia. - Google Patents

Composici??n farmaceutica para el tratamiento de xeroftalmia y xerostomia.

Info

Publication number
MX2007003994A
MX2007003994A MX2007003994A MX2007003994A MX2007003994A MX 2007003994 A MX2007003994 A MX 2007003994A MX 2007003994 A MX2007003994 A MX 2007003994A MX 2007003994 A MX2007003994 A MX 2007003994A MX 2007003994 A MX2007003994 A MX 2007003994A
Authority
MX
Mexico
Prior art keywords
xerophthalmia
pharmaceutical composition
xerostomia
xerostomia treatment
treatment
Prior art date
Application number
MX2007003994A
Other languages
English (en)
Inventor
Yohei Okada
Ken Ikeda
Fumikazu Wanibuchi
Keiichi Yoshihara
Hiromu Kondo
Hiroyuki Kojima
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2007003994A publication Critical patent/MX2007003994A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Proporcionar un agente terapeutico para xeroftalmia y xerostomia que se encuentre libre de efectos indeseables. La administracion del compuesto A ha realizado la promocion de secrecion de saliva y lagrimas sin la transpiracion y a traves de la liberacion sostenida, ha realizado ademas la promocion de la multiplicacion de las celulas de glandula salival y glandula lagrimal.
MX2007003994A 2004-10-05 2005-10-04 Composici??n farmaceutica para el tratamiento de xeroftalmia y xerostomia. MX2007003994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004292611 2004-10-05
PCT/JP2005/018310 WO2006038596A1 (ja) 2004-10-05 2005-10-04 涙液及び唾液乾燥症治療用医薬組成物

Publications (1)

Publication Number Publication Date
MX2007003994A true MX2007003994A (es) 2007-06-15

Family

ID=36142669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003994A MX2007003994A (es) 2004-10-05 2005-10-04 Composici??n farmaceutica para el tratamiento de xeroftalmia y xerostomia.

Country Status (15)

Country Link
US (2) US20070105934A1 (es)
EP (1) EP1712230A1 (es)
JP (1) JPWO2006038596A1 (es)
KR (1) KR20070061578A (es)
CN (1) CN101031297A (es)
AU (1) AU2005290532A1 (es)
BR (1) BRPI0516468A (es)
CA (1) CA2582615A1 (es)
IL (1) IL182124A0 (es)
MX (1) MX2007003994A (es)
NO (1) NO20072328L (es)
RU (1) RU2007116944A (es)
TW (1) TW200616628A (es)
WO (1) WO2006038596A1 (es)
ZA (1) ZA200702784B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082381A1 (en) * 2005-07-26 2009-03-26 Akiharu Isowaki Percutaneously Absorbable Ophthalmic Preparation
US10338203B2 (en) 2011-09-09 2019-07-02 Siemens Medical Solutions Usa, Inc. Classification preprocessing in medical ultrasound shear wave imaging
JP6526475B2 (ja) * 2015-04-30 2019-06-05 サンスター株式会社 経皮唾液腺投与用の唾液分泌促進剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2683783B2 (ja) * 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
RU2121830C1 (ru) * 1992-09-18 1998-11-20 Яманоути Фармасьютикал Ко., ЛТД Гидрогелевый препарат с длительным высвобождением лекарства
JPH07126163A (ja) * 1993-10-08 1995-05-16 Theratech Inc 制御放出性ピロカルピン送達システム
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US20020142033A1 (en) * 1998-05-05 2002-10-03 Gupta Suneel K. Method for treating incontinence
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
JP2003063964A (ja) * 2001-08-28 2003-03-05 Senju Pharmaceut Co Ltd ドライアイまたはドライアイを伴なう疾病の予防治療剤

Also Published As

Publication number Publication date
CA2582615A1 (en) 2006-04-13
WO2006038596A1 (ja) 2006-04-13
RU2007116944A (ru) 2008-11-20
IL182124A0 (en) 2007-07-24
US20080131511A1 (en) 2008-06-05
US20070105934A1 (en) 2007-05-10
ZA200702784B (en) 2008-09-25
CN101031297A (zh) 2007-09-05
AU2005290532A1 (en) 2006-04-13
EP1712230A1 (en) 2006-10-18
NO20072328L (no) 2007-06-29
JPWO2006038596A1 (ja) 2008-05-15
TW200616628A (en) 2006-06-01
BRPI0516468A (pt) 2008-09-09
KR20070061578A (ko) 2007-06-13

Similar Documents

Publication Publication Date Title
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
EA200901319A1 (ru) Композиции для назального введения
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
MX2010010026A (es) Agente para tratar enfermedad.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA96449C2 (en) Stable laquinimod preparations
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
IL169169A (en) Stable topical drug delivery compositions
SI1819227T1 (sl) Farmacevtska formulacija decitabina
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
MX2007006558A (es) Formulaciones topicas de nepafenac.
CR8603A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
PL1976544T3 (pl) Sposób stosowania ekstraktu z guawy i kompozycja zawierająca ekstrakt z guawy
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
MX2007003994A (es) Composici??n farmaceutica para el tratamiento de xeroftalmia y xerostomia.
AU2003202550A1 (en) Pharmaceutical formulations with modified release
MX2009002985A (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (tsh).
SE0203817D0 (sv) New composition
MX2009003930A (es) Novedoso cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato.
AR048068A1 (es) Piperazinas derivadas de urea para el tratamiento de endometriosis
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MX2025012819A (es) Compuestos bifuncionales para degradar braf a traves de la via del proteosoma de ubiquitina
MD20040296A (ro) Compoziţie farmaceutică, conţinând oxcarbazepină cu eliberare prelungită a ingredientului activ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal